Search

Search Constraints

You searched for: Author/Creator Melear, J.

Search Results

1. INTERIM ANALYSIS OF PHASE IIIB MAGNIFY STUDY OF INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA. (12th June 2019)

2. MAGNIFY PHASE IIIB INTERIM ANALYSIS: FIRST REPORT OF INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA. (12th June 2019)

3. P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY (SGN35 027 PART B). (23rd June 2022)

4. The AXL inhibitor, TP-0903, reverses EMT and shows activity in non-small cell lung cancer preclinical models. (October 2022)